We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group.
- Authors
Heinrich, Michael C; Owzar, Kouros; Corless, Christopher L; Hollis, Donna; Borden, Ernest C; Fletcher, Christopher D M; Ryan, Christopher W; von Mehren, Margaret; Blanke, Charles D; Rankin, Cathryn; Benjamin, Robert S; Bramwell, Vivien H; Demetri, George D; Bertagnolli, Monica M; Fletcher, Jonathan A
- Abstract
Imatinib mesylate is standard treatment for patients who have advanced gastrointestinal stromal tumor (GIST), but not all patients benefit equally. In previous studies, GIST genotype correlated with treatment outcome and optimal imatinib dosing.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Vol 26, Issue 33, p5360
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2008.17.4284